Company intelligence / Profile preview

HaemaLogiX

Woolloomooloo/Sydney, New South Wales, Australiahaemalogix.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 2

Overview

KappaMab, the lead monoclonal antibody targeting KMA, has shown excellent safety and efficacy in relapsed/refractory multiple myeloma patients. Interim Phase IIb data validate its potential to boost standard-of-care treatments with a favorable safety profile. Final results were anticipated late in 2021. The company also holds exclusivity over both the targets and their corresponding antibodies, strengthening its IP position

Therapeutic areas: OncologyHematology
Modalities: monoclonal antibodies (mAbs)autologous CAR-T cellsbispecific antibodies
Industry: Biotech

Drug pipeline

6 assets

KMA.CAR-T

5 more assets in the full pipeline.

Request access →

Partnerships

Strategic partnerships for commercialization are a stated goalPlatinum Asset Management invested as an institutional investorCollaborations with leading academic centers globally in MM & AL Amyloidosis therapy

Beyond the preview

Go deeper on HaemaLogiX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HaemaLogiX.

Explore the full profile